Mesothelioma: Chemo Combination Improves Survival In Asbestos-related Cancer
People with mesothelioma — a form of cancer associated with asbestos exposure — have a higher survival rate when treated with a combination of two cancer drugs, a large multicenter study finds. Read more..
Tomorrow, the wife of deceased mesothelioma victim Bernie Bantonwill officially launch the Asbestos Research Group in Brisbane. Banton campaigned for aggressive asbestos legislation in Australia, acting as an advocate for safer asbestos policy. The new research group will focus on studying mesothelioma and non-cancerous asbestos-related diseases. Beyond research, the group aims to improve treatment and [...]
Tomorrow, the wife of deceased mesothelioma victim Bernie Bantonwill officially launch the Asbestos Research Group in Brisbane. Banton campaigned for aggressive asbestos legislation in Australia, acting as an advocate for safer asbestos policy. The new research group will focus on studying mesothelioma and non-cancerous asbestos-related diseases. Beyond research, the group aims to improve treatment and quality [...]
Source: http://blog.mesorc.com/2008/06/10/new-asbestos-research-group-launches-in-memory-of-victim-advocate/
Charcot-Marie Tooth Disease is the most common neuromuscular disease in the world. It is sometimes referred to as "Hereditary Motor and Sensory Neuropathy. It is affected approximately 1 in 2,500 people in the United States. CMT affects both motor and sensory nerves. Read more Read more..
Merck & Co., Inc announced today its investigational trial of vorinostat (ZOLINZA®), the Company’s oral histone deacetylase (HDAC) inhibitor, in patients with advanced malignant pleural mesothelioma has progressed into Phase III investigation and is currently enrolling patients who previously failed or are intolerant to prior therapies such as chemotherapy. The decision to move forward follows [...]
Merck & Co., Inc announced today its investigational trial of vorinostat (ZOLINZA®), the Company’s oral histone deacetylase (HDAC) inhibitor, in patients with advanced malignant pleural mesothelioma has progressed into Phase III investigation and is currently enrolling patients who previously failed or are intolerant to prior therapies such as chemotherapy. The decision to move forward follows [...]
Source: http://blog.mesorc.com/2008/06/06/mesothelioma-treatment-moves-to-phase-iii-trial/
Current predictions of the future incidence of asbestos-related disease have been substantially underestimated, according to new modelling to be presented in Melbourne today by an epidemiologist from the Australian National University. Read more..
Tags: tumors, loss of appetite, pleural mesothelioma, mesothelioma patients, period of time, ray machine, clinical trial, abdominal cavity, pleural, experience
